SBIR Phase I: Novel COVID-19 Dual-function Therapeutic/Vaccine Product — NSF Award to PARAMITA THERAPEUTICS, INC. (CA, $255,990)
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to develop a new class of dual-function therapeutic/vaccine products that can prevent viruses from entering cells (therapeutic effect) while also stimulating immunity to viruses (vaccine effect). The proposal has immedi
| Award title | SBIR Phase I: Novel COVID-19 Dual-function Therapeutic/Vaccine Product |
|---|---|
| Award ID | 2112166 |
| Awardee | PARAMITA THERAPEUTICS, INC. |
| City | SAN DIEGO |
| State | CA |
| Amount obligated | $255,990 |
| Principal investigator | Sang Van |
| Program | SBIR Phase I |
| Start date | 05/01/2021 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to develop a new class of dual-function therapeutic/vaccine products that can prevent viruses from entering cells (therapeutic effect) while also stimulating immunity to viruses (vaccine effect). The proposal has immediate impact in that it seeks to synthesize a compound that can be used to treat patients with COVID-19, caused by SARS CoV-2. Specifically, the novel solution both prevents SARS-CoV |
| Source | NSF Awards |
$799/mo
Try NSFGrants →